US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Fate Therapeutics, Inc. - Common Stock
(NQ:
FATE
)
2.320
+0.020 (+0.87%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
October 01, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
September 25, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
September 16, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
September 09, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
September 03, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
↗
August 31, 2026
One of J&J's investments stands head-and-shoulders above the rest.
Via
The Motley Fool
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
August 14, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
August 13, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
July 09, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
July 06, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
July 01, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Appoints Laura Hamill to Board of Directors
June 15, 2026
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
June 12, 2026
From
Equity Insider
Via
GlobeNewswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From
Biotech Insider
Via
GlobeNewswire
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
June 04, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
June 01, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 21, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
May 20, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END
Via
FinancialNewsMedia
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END
Via
FinancialNewsMedia
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 11, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
May 05, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 04, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
April 30, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR
April 16, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
April 09, 2026
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
